Nur Efe IRİS, Aslıhan DEMİREL, Safiye KOÇULU, Esin ÇEVİK, Reyhan Diz KUCUKKAYA

Quinolone resistance of gram negative bacteria from the patients with malignancies and relationship with prophylaxis

Fluoroquinolones are the most commonly used antibiotics for the treatment and prophylaxis of patients with malignancies. But resistance development is a big problem.With the aim of identifying the epidemiological data about the local fluoroquinolone resistance of the patients with malignancies followed up in the hospital or on outpatient basis, fluoroquinolone resistance of gram negative bacteria isolated from different materials of these patients was investigated. In our hospital, from January 2013 to August 2014, gram negative isolates that were isolated from the samples of patients with malignancies followed-up by Hematology and Oncology Departments were retrospectively analyzed. Within a period of one and a half years, 227 Gram negative bacteria were isolated from the materials of the patients hospitalized in our hospital. Quinolone resistance rates were 63% for E.coli, 49% for Klebsiella pneumoniae, 34% for Pseudomonas aeruginosa, 72% for Acinetobacter baumannii , with a mean of 52% for all Gram negatives. When patients who received and who did not receive quinolone prophylaxis were compared, resistance rate was 57% (26/61) for those receiving prophylaxis and 50 %( 83/166) for those who did not. In conclusion, fluoroquinolone resistance rates were considerably high and it was higher in the patients who received quinolone prophylaxis, but it wasn't statistically significant. In the oral treatment of febrile neutropenic patients, empirical treatment aims at Gram negative pathogens and considers quinolon es as the first choice; however this data raises a suspicion about the efficacy and adequacy of quinolones

PDF

___

1. Freifeld AG, Bow EJ, Sephowitc KA Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America.. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases societyof America. Clin Infect Dis. 2011;52(4):e56-93.

2. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE).http//evs-nci.nih.gov/ftp1/CTCAE/CTCAE- 4.03_2010-06-14 Quick Reference 5x7.pdf (Accessed on February 16, 2012).

3. Garnica M, A Nouer SA, Pellegrino F, Moreira BM, Maiolino A, Nucci M. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infectious Diseases. 2013;13:356.

4. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D,Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. () Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977-87.

5. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R,Gollins S, Stanley A; Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988-98.

6. Gafter -Gvilli A, Paul M, Fraser A, Leibovici L Effect of quinolone prophylaxis in afebril neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59(1):5-22.

7. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disc Susceptibility Tests, Approwed Standard M2-A7, NCCLS, Wayne. 2000.

8. Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200-10.

9. Aktepe OC, Aşık G, Çetinkol Y, Biçmen M, Gülay Z () Investigation of Plasmid-mediated Quinolone Resistance in Escherichia coli Strains.Mikrobiol bul. 2012;46(1):9-16.

10. Chen CY, Tsay W,Tang JL, Tien HF, Chen YC, Chang SC, Hsueh PR. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138(7):1044-51.

11. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone resistant Escherichia coli among patients with haematological malignancies:results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61(3):721-8.

12. Öztürk R. Rational drug use for febril neutropenic patients. XXXIX. National Hematology Congress, book, 2013;p:76-80.

13. Schelenz S, Nwaka D, Hunter PR. Longitudinal surveillance of bacteremia in hematology and oncology patients at a UK cancer centre and the impact of ciprofloxacin use on antimicrobial resistance. J Antimicrob Chemother. 2013;68(6):1431-8.

14. Hamidi A, Başaran S, Çağatay A, Özsüt H, Atay K, Avşar N, DizKüçükkaya R, Eraksoy H. Organisms Isolated From Blood Cultures, Their Antimicrobial Susceptibilities and patient Characteristics in patients with Febrile Neutropenia. Journal of KLIMIK. 2009;22(3):88- 91.

15. Tunçcan G, Şenol E, Sarı N, Sezer B, Özkurt N, Sucak GT, Yalçın M. Prevalance of the Organisms Isolated From Blood Cultures and their resistance patterns in patients with febrile neutropenia. Congress of Febril Neutropenia, congress book 2008; P017, p.158.

16. Yurtsever GS, Çeken N, Payzın B, Kurultay N, Topçugil F, Demirci M. Bacterial spectrum and Antimicrobial Susceptibility profile in blood cultures of patients with febrile neutropenia . Nobel Med. 20117;(1):74- 78.